Three-quarters of IT decision-makers at pharmaceutical companies plan to invest from $500,000 to $5 million in AI this year which, for many, doubles their budgets over the past year. That’s one of the findings based on the cross-industry research report involving 1,400 IT decision makers from Rackspace and AWS. “In terms of AI adoption, almost…
Genentech’s lab in the loop aims to tap the power of quantity for quality drug discovery
We can design chips that power self-driving cars and create physically-realistic video footage based on text descriptions. Yet, as Genentech’s Aviv Regev pointed out in a session about the company’s lab in the loop at NVIDIA’s GTC conference, the humble cells within us operate with a complexity that still eludes our full understanding. It turns out that a cell is itself like a computational device…
Denmark teams up with Novo Nordisk Foundation, NVIDIA to launch visionary AI research center
A collaboration between the Novo Nordisk Foundation, the Export and Investment Fund of Denmark (EIFO), and NVIDIA will establish a national AI Innovation Centre in Denmark focused on accelerating research and innovation in fields including healthcare, life science, and quantum computing. The initiative is led on the Danish side by the Novo Nordisk Foundation, which…
Lantern Pharma aims to take drug to phase 3 for $100-200 million with AI-powered approach
Lantern Pharma’s AI-powered sprint Lantern Pharma (NASDAQ: LTRN), a publicly traded clinical-stage biotech company with a market cap of around $79 million as of mid-March 2024, is shooting for developing $200 million drugs with a machine learning-based platform. The oncology-focused firm Lantern Pharma, profiled last year, has advanced its new drug (LP-284) to a Phase…
Microsoft and 1910 Genetics: AI-powered partnership targets billion-dollar savings and growth in drug discovery
The pharmaceutical industry is at a critical juncture: AI and other technological advances offer unprecedented potential, yet the cost of developing new drugs has ballooned for decades, surpassing $2 billion in recent years with the projected return on investment (ROI) falling to a mere 1.2% in 2022, according to Deloitte. Another dimension of the problem…
Two-thirds of pharma companies plan to up IT investments in 2024, survey finds
Two out of three pharma companies (67%) plan to ramp up investment in IT, including AI, over the next 12 months, according to a survey from the cloud vendor Rackspace Technology and Dell/VMware conducted in October 2023. About the same amount, 68%, reported challenges in recruiting and hiring talent skilled in cloud and AI technology.…
Insilico Medicine’s latest AI-engineered drug ISM5411 could provide a novel approach for treating IBD
Capping off a busy 2023, Insilico Medicine has announced a potentially first-in-class oral PHD inhibitor for the treatment of inflammatory bowel disease (IBD). ISM5411 is the fifth AI-backed drug candidate from Insilico Medicine to reach clinical stages. ISM5411 targets prolyl hydroxylase domain (PHD) enzymes via modulation of the hypoxia-inducible factor (HIF) pathway, which is involved…
50 of the best-funded biotechs of 2023
As the year draws to a close, it is clear that molecular science and diagnostics is the hottest funding area in the biotech industry. In an analysis of 50 of the best-funded biotechs of 2023 focused on human health, molecular and science and diagnostics startups collectively attracting roughly $945 million, dwarfing the figures in other…
Verseon’s hybrid AI platform aims to unlock a universe of drug candidates
The clinical-stage company Verseon (Fremont, California) is unique among companies exploring the use of AI in drug discovery given its focus on what it calls the “uncharted” chemical space. While Big Pharma companies typically test compounds from their collections for specific diseases, these collections often have constraints and overlapping compounds. Adityo Prakash, CEO of Verseon,…
BenevolentAI is pioneering AI-driven drug discovery methods
“Can we treat chronic inflammation in ulcerative colitis by reversing immune cell activation in colonic mucosa?” That’s an example of a biological question that the AI-enabled drug discovery firm BenevolentAI (AMS:BAI) would ask when exploring a new drug target. Incorporating a disease, sign, mechanism and tissue into a single question provides focal points for the…
Using AlphaFold, Insilico Medicine produces AI drug discovery in record time
An international group of researchers employed DeepMind’s deep learning-driven AlphaFold protein structure database to design and synthesize a potential hepatocellular carcinoma (HCC) drug in only 30 days. The AI drug discovery project consisted of Insilico Medicine, the University of Toronto’s Acceleration Consortium and researchers including Nobel laureate Michael Levitt. The team applied AlphaFold to Insilico’s…